Navigation Links
La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert
Date:12/10/2009

business but ADMP does. All LPJC has is NET $3MM in cash and nothing else. As in all reverse mergers, the surviving merged company issues stock to complete the merger. In this merger, regardless of what the market price is, the PPS for LJPC is the $3 million divided by the number of LJPC shares (66 million + 4 million options=70 million). So the most LJPC shares are worth in the merger is about 4-5 cents. LJPC is first performing a reverse stock split to match prices with ADMP. S0 if ADMP is at about 25 cents, its average for the last several months, LJPC shareholders will at least a 5:1 reverse split for the adjusted share price, and get ONE share in the new company. Current ADMP shareholders will also get one share in the company. In the end, LPJC shareholders will only own 10-20% of the company. So at the current LJPC share price, they will see about a NEGATIVE 80% return on their investment... to continue reading the discussion thread visit TapeBeat.Com.

This information was compiled by TapeBeat.Com staff writers with no trading in either stock. TapeBeat.Com is not associated with either company and has received no incentive to disseminate this information, which is the opinion of the poster.

TapeBeat.Com is the place for the serious investor, who wishes to make "Each Trade Better". This is accomplished by a sharing of research and trading strategies with an experienced group of investors. The TapeBeat portfolio is one of the highest ranked on Covestor and is an example of the results that are attainable through the 'free sharing' of information that occurs on TapeBeat.Com. Sign up now to receive important trading alerts for free, or to share your research and opinions.

By viewing information from TapeBeat.Com you agree to our

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. La Jolla Institute for Allergy & Immunology Wows With New Website
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... N.J., Aug. 14 DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... financial results for the second quarter of 2009. , ... National Institutes of Health (NIH) grants, for the second quarter of ... second quarter of 2008. Revenues for the first half of ...
... , ... Virtual Skin™ Technology from CellWorks Group Demonstrates Possibilities for ISP,s Vincience™ Biofunctional Ingredients, ... ... therapy design company, and ISP Personal Care, a global supplier of advanced personal ...
... , , WORCESTER, Mass., Aug. 13 ... Lanza, its Chief Scientific Officer, is featured on Deepak Chopra,s Wellness Radio ... pm - 1 pm ET; Replays 1 pm - 4 am (Sunday) ... research at ACTC and his new book "Biocentrism." SIRIUS XM Stars ...
Cached Biology Technology:DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 5Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 2Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 3Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 4Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 3
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... and smooth sailing for oceanic vessels has been impeded ... pollution and greenhouse gas emissions that impact the Earth,s ... and James Corbett examines "Emission Tradeoffs among Alternative Marine ... Gas Oil, and Marine Diesel Oil," in a recent ...
... WASHINGTON, Sept. 8 The 2009 Force Protection ... County Regional Airport,Stafford, VA, and Marine Corps Base, ... is: Impacting the Global War on Terror., ... kind featuring live,presentations of commercial off-the-shelf equipment solutions ...
... paper by a team of researchers led by Shahriar ... University of Notre Dame, provides important new insights into ... The cell wall is a critically important entity ... a rigid entity encasing the bacterium, and antibiotics are ...
Cached Biology News:Fuel emissions from marine vessels remain a global concern 22009 Force Protection Equipment Demonstration Set for Next May 19-21 2
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: